The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | The impact of durvalumab on the SCLC treatment landscape
Suresh Senan, MRCP, FRCR, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands, comments on the current status of durvalumab in the treatment of small cell lung cancer (SCLC). Durvalumab has obtained global regulatory approval following the ADRIATIC trial (NCT03703297), but the NRG-LU005 (NCT03811002) showed that concurrent immunotherapy and chemoradiotherapy was not as efficacious. Further trials are need to determine the optimal timing and approach of immunotherapy, including sequential and concurrent regimens, to establish the best standard of care for this patient population. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
